Five-year OS rates were 22% vs. 8% in PD-L1 < 1%, 18% vs. 11% in PD-L1 ≥ 1%, 18% vs. 7% in squamous, and 19% vs. 12% in non-squamous NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.